BRCA1 and ovarian carcinoma: Currently, with the introduction of poly (ADP-ribose) polymerase (PARP) inhibitors, for BRCA1/2 mutated breast and ovarian cancer patients [4], the exact relationship between BRCA1/2 genes and sporadic TNBC/HGSC needs to be further investigated.